Kiran Dole started her pharma career with Novartis Pharmaceuticals in NJ, where she joined as a Clinical Trial Leader in the Translational Sciences group, designing and overseeing early phase clinical studies. She transitioned to NIBR in 2008 where the focus of her work evolved to the identification and implementation of novel technologies to design more data-rich, and patient-centric trials. Her passion for innovative technologies has led her to a career at Pear Therapeutics as the Director of Clinical Operations. Kiran holds a PharmD from SUNY Buffalo as well as a Bachelors in Biochemistry from the University of Toronto .
